BRCA and NACT in TNBC Patients

Inclusion Criteria: * Written informed consent. * Age older than 18 years. * Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. * Tumor lesion in the breast with a palpable size of ≥ 2 cm and/or ≥ 1.5 cm by ultrasound or magnetic resonance imaging (MRI). In case of inflammatory carcinoma, the extent of inflammation can be used as measurable lesion. * American Joint Commission on Cancer stage II or III invasive breast cancer. * Known estrogen (ER)- and progesterone (PgR)-receptor negative tumors. * Known HER-2/neu negative tumors, defined as IHC 1+/2+ or SISH not amplified. * Patients suitable for neoadjuvant chemotherapy * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 or Karnowsky performance status index at least 80%. * Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 1 month prior to registration. * Laboratory requirements: * Hematology: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, Hemoglobin ≥ 10 g/dL. * Hepatic function: Total bilirubin \< 1 x UNL, ASAT (SGOT) and ALAT (SGPT)≤ 2.5 x UNL, Alkaline phosphatase ≤ 5 UNL. Patients with ASAT and / or ALAT \> 1.5 x UNL associated with alkaline phosphatase \> 2.5 x UNL are not eligible for the study. * Renal function: Creatinine ≤ 2 mg/dL, \< 1,25 UNL (or the calculated creatinine clearance ≥ 60 mL/min). * Paraffin tumor tissue block made available. * Availability to provide the set up of the histological preparations for molecular analysis. * Negative pregnancy test (urine or serum). * Patients must be available and compliant for treatment and follow-up. Exclusion Criteria: * Patients candidate for adjuvant chemotherapy. * Evidence of distant metastasis. * Prior chemotherapy for any malignancy. * Prior radiation therapy for breast cancer. * Pregnant or lactating patients. * Inadequate general condition. * Previous malignant disease. * Known or suspected congestive heart failure (\>NYHA I) and/or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension, rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease. * History of significant neurological or psychiatric disorders that would prohibit the understanding and giving of informed consent.